BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

• ClinicalTrials.gov Identifier: NCT03639844
• Expanded Access Status: No longer available
• First Posted: August 21, 2018
• Last Update Posted: October 5, 2020
• Sponsor: Bellicum Pharmaceuticals
• Information provided by (Responsible Party): Bellicum Pharmaceuticals

Study Description

Brief Summary:

Providing access of BPX-501 gene modified T cells and rimiducid to pediatric patients who do not meet the eligibility criteria of the BP-U-004 study.

Condition or disease	Intervention/treatment
Hurler Syndrome; Inherited Metabolic Disorder; Lysosomal Storage Disorder; Metachromatic Leukodystrophy; Inborn Errors of Metabolism	Biological: rivogenlecleucel; Drug: rimiducid

Detailed Description:

This is an expanded access protocol of BPX-501 T cells infused after T cell-depleted HSCT in pediatric patients with non-malignant hematologic disorders eligible for treatment on the BP-U-004 study.

The purpose of this protocol is to provide access to the CaspaCIDe system combination product (BPX-501 gene modified T cells and rimiducid) to patients on a case by case basis who do not meet the BP-U-004 protocol eligibility criteria. BPX-501 infusion can enhance immune reconstitution with the potential for reducing the severity and duration of severe acute GVHD.

Study Design

• Study Type: Expanded Access
• Expanded Access Type: Individual Patients

See clinical trials of the intervention/treatment in this expanded access record.

• Official Title: Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders

Interventions

Intervention Details:

• Biological: rivogenlecleucel
  BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.
  Other Name: BPX-501 T cells
• Drug: rimiducid
  Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD
  Other Names:

  • AP1903
  • Rimiducid for Injection
  • AP1903 for Injection

Eligibility Criteria

• Ages Eligible for Study: 3 Months to 21 Years (Child, Adult)
• Sexes Eligible for Study: All

Criteria

Inclusion Criteria:

1. Males or females
2. Age < 21 years and > 3 months
3. Life expectancy > 10 weeks
4. Patients deemed eligible for allogeneic stem cell transplantation.

5. Non-malignant disorders including:

   1. inherited metabolic disorders such as adrenal leukodystrophy;
   2. lysosomal storage disorders such as Hurler syndrome or metachromatic leukodystrophy
   3. other inborn errors of metabolism
6. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative evaluated using high resolution molecular typing).
7. A minimum genotypic identical match of 5/10 is required.
8. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, and HLA- DRB1.
9. Lansky/Karnofsky score > 50
10. Signed written informed consent

3.2 Subject exclusion criteria

1. Age < 3 months or >21 years

2. Patients with non-malignant disorders eligible for treatment on the BP-U-004 study:

   1. primary immune deficiencies,
   2. severe aplastic anemia not responding to immune suppressive therapy,
   3. osteopetrosis,
   4. selected cases of hemoglobinopathies and
   5. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML)
3. Greater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at the time of inclusion
4. Patient receiving an immunosuppressive treatment for GVHD treatment due to a previous allograft at the time of inclusion
5. Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance < 30 ml / min)
6. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)
7. Current active infectious disease (including positive HIV serology or viral RNA)
8. Serious concurrent uncontrolled medical disorder
9. Pregnant or breast feeding female patient

10. Lack of parents'/guardian's informed consent.

    -

Contacts and Locations

Locations

United States, California

Children's Hospital Los Angeles

Los Angeles, California, United States, 90027

Stanford University; Division of Pediatric Stem Cell Transplant & Regenerative Medicine

Palo Alto, California, United States, 94304

Sponsors and Collaborators

Bellicum Pharmaceuticals

Investigators

• Study Director: Bellicum Pharmaceuticals; Bellicum Pharmaceuticals, Inc.

More Information

• Responsible Party: Bellicum Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT03639844
• Other Study ID Numbers: BP-C-004
• First Posted: August 21, 2018
• Last Update Posted: October 5, 2020
• Last Verified: October 2020

Additional relevant MeSH terms:

Leukodystrophy, Metachromatic; Metabolism, Inborn Errors; Mucopolysaccharidosis I; Lysosomal Storage Diseases; Metabolic Diseases; Disease; Pathologic Processes; Genetic Diseases, Inborn; Hereditary Central Nervous System Demyelinating Diseases; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Sulfatidosis; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Leukoencephalopathies; Demyelinating Diseases; Lipidoses; Lipid Metabolism, Inborn Errors; Lipid Metabolism Disorders; Mucopolysaccharidoses; Carbohydrate Metabolism, Inborn Errors; Mucinoses; Connective Tissue Diseases